1198284-94-4

Basic information

• Product Name: 2-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE
• Synonyms: 2-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE;9-Boc-1-oxo-2,9-diazaspiro[5.5]undecane;9-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE;9-Boc-1-oxo-2,9-diazaspiro[5.5]undecane - X10875
• CAS NO: 1198284-94-4
• Molecular Formula: C₁₄H₂₄N₂O₃
• Molecular Weight: 268.35196
• Mol File: 1198284-94-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 438.0±38.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 16.27±0.20(Predicted)
• CAS DataBase Reference: 2-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE(1198284-94-4)
• EPA Substance Registry System: 2-Boc-2,9-DIAZASPIRO[5.5]UNDECAN-1-ONE(1198284-94-4)

Safety Data

• Hazardous Substances Data: 1198284-94-4(Hazardous Substances Data)

Usage

General Description

2-Boc-2,9-Diazaspiro[5.5]undecan-1-one is a specific type of chemical compound from the group of organic compounds known as 'bicyclic monoterpenoids'. It has been identified within the category of spiro compounds. Spiro compounds are organic compounds featuring a spiroatom, a single atom that is the only common member of two rings. More specific details about this chemical, such as its molecular weight, chemical formula, or possible uses, are not commonly available as it may not be widely researched or used in common applications. Its complexity suggests specialized uses in scientific research or targeted industrial applications.

Upstream product

• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1313236-57-5 1-tert-butyl 4-ethyl 4-(2-cyanoethyl)piperidine-1,4-dicarboxylate 

Downstream Products

• 1313237-05-6 tert-butyl 1-oxo-2-((1-tosyl-1H-indol-3-yl)methyl)-2,9-diazaspiro[5.5]undecane-9-carboxylate 
• 1313237-08-9 2-((1-tosyl-1H-indol-3-yl)methyl)-2,9-diazaspiro[5.5]undecan-1-one trifluoroacetate 
• 1313237-10-3 9-(quinolin-3-yl)-2-((1-tosyl-1H-indol-3-yl)methyl)-2,9-diazaspiro[5.5]undecan-1-one 
• 1313234-50-2 2-(2-(2H-1,2,3-triazol-2-yl)benzyl)-9-(quinoxalin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one 
• 1313237-12-5 tert-butyl 2-(2-(2H-1,2,3-triazol-2-yl)benzyl)-1-oxo-2,9-diazaspiro[5.5]-undecane-9-carboxylate 
• 1373766-12-1 9-(4,6-dimethylpyrimidin-2-yl)-2-((1-methyl-4-phenyl-1H-pyrazol-3-yl)methyl)-2,9-diazaspiro[5.5]undecan-1-one 
• 1373766-11-0 9-(4,6-dimethylpyrimidin-2-yl)-2-((4-phenyl-1H-pyrazol-3-yl)methyl)-2,9-diazaspiro[5.5]undecan-1-one 
• 1457940-75-8 9-(4,6-dimethylpyrimidin-2-yl)-2-((5-methoxy-1H-indol-3-yl)methyl)-2,9-diazaspiro[5.5]undecan-1-one 
• 1313234-06-8 2-benzyl-9-(quinoxalin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one 

Relevant articles and documents

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.